CAR T Cells with Mutant PGC-1α for Metabolic Fitness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chimeric antigen receptor (CAR) T cells face challenges in persistence and effector function, particularly in achieving central memory phenotypes that balance metabolic fitness with cytotoxic potential, which is crucial for durable tumor cell eradication and metabolic resilience in nutrient-depleted tumor microenvironments.
Innovation Solution
Overexpressing PGC-1α, a master regulator of mitochondrial biogenesis and metabolic fitness, in CAR T cells to enhance the frequency of central memory T cells, which involves engineering CAR T cells to express mutant PGC-1α variants that resist degradation, thereby augmenting metabolic fitness without compromising cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If CAR T cells are engineered to achieve central memory phenotypes with enhanced metabolic fitness, then persistence and expansion in tumor microenvironment are improved, but cytotoxic potential may be compromised
Solution Approach 1:
The patent modifies the metabolic parameters of CAR T cells by overexpressing PGC-1α, which shifts the metabolic profile toward enhanced oxidative phosphorylation and mitochondrial biogenesis. This parameter change enables central memory phenotype development with improved persistence while maintaining cytotoxic function through balanced metabolic reprogramming
Solution Approach 2:
The invention creates a composite functional profile in CAR T cells by combining central memory phenotype characteristics with enhanced metabolic fitness through PGC-1α overexpression. This composite approach integrates persistence, expansion capacity, and cytotoxic potential into a unified cell population with superior therapeutic efficacy
2Use of energy by moving object
If PGC-1α is overexpressed to enhance metabolic fitness, then mitochondrial biogenesis and oxidative metabolism are improved, but degradation by GSK3β and ubiquitination may reduce PGC-1α stability
Solution Approach 1:
The patent applies preliminary anti-action by introducing mutations in PGC-1α that preemptively resist degradation by GSK3β and other ubiquitination mechanisms. These mutant PGC-1α variants are designed to evade the cellular degradation pathways before they can act, thereby stabilizing PGC-1α levels and maintaining enhanced metabolic fitness
Solution Approach 2:
The invention changes the stability parameter of PGC-1α by introducing specific mutations that alter its interaction with degradation pathways. This parameter change increases PGC-1α half-life and prevents ubiquitination-mediated degradation, ensuring sustained mitochondrial biogenesis and metabolic reprogramming
3Productivity
If CAR T cells are designed for peak expansion after infusion, then proliferative capacity is improved, but differentiation toward terminally differentiated or exhausted phenotypes may increase
Solution Approach 1:
The patent modifies the metabolic parameters of CAR T cells by enhancing oxidative phosphorylation and mitochondrial function through PGC-1α overexpression. This metabolic parameter change supports sustained proliferation while preventing differentiation toward exhausted phenotypes, as oxidative metabolism provides the energy needed for long-term persistence and functional maintenance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly increases the frequency of central memory T cells, enhancing their metabolic resilience and cytotoxic capabilities, leading to improved therapy efficacy by maintaining cytotoxic potential while ensuring persistence and expansion in tumor microenvironments.
Implementation Method 1
PGC-1α is a 798 a.a. transcriptional coactivator with no DNA binding domain or enzymatic activity. As a coactivator, it can bind with a broad set of transcription factors and induce the upregulation of many complex transcriptional programs.
Implementation Method 2
Central memory T cells rely heavily on fatty acid oxidation and oxidative phosphorylation in mitochondria to synthesize ATP requiring augmented metabolic fitness.
Implementation Method 3
Central memory T cells rely heavily on fatty acid oxidation and oxidative phosphorylation in mitochondria to synthesize ATP
Implementation Method 4
Persistent memory cells are characterized as having increased mitochondrial biomass with tubular morphology and a greater use of oxidative metabolism that relies more on the TCA cycle and ETC to produce ATP.
Implementation Method 5
At rest, constitutively expressed GSK3β ubiquitinates PGC-1α for proteasomal degradation
Implementation Method 6
GSK3β—ubiquitinates PGC-1α (T295) for proteosomal degradation
Implementation Method 7
During CAR and TCR signaling the PI3K signaling axis activates Akt, which phosphorylates and deactivates GSK3β and deactivates PGC-1α.
Data Source
AI summary
Disclosed herein are CAR-T cells engineered to express mutant PGC-1α, wildtype NT-PGC-1α, or mutant NT-PGC-1α to enhance or prevent degradation of metabolic fitness. Also disclosed herein is a method for enhancing metabolic fitness of a CAR-T cell by transducing the CAR-T cell with a vector encoding a mutant PGC-1α, wildtype NT-PGC-1α, or mutant NT-PGC-1α. Also disclosed is a method for producing CAR-T cells that involves transducing activated T cells with a viral vector encoding a mutant PGC-1α, wildtype NT-PGC-1α, or mutant NT-PGC-1α polypeptide.